Endpoints News 3. Juni 2026 Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
Endpoints News 2. Juni 2026 FDA details flexibilities for new cell and gene therapies to leverage past data
Endpoints News 2. Juni 2026 What’s next for VEGF? #ASCO26 offered clues, but answers will have to wait
Endpoints News 2. Juni 2026 Male contraception startup closes $92.5M Series B; Novartis bets on actinium
Endpoints News 2. Juni 2026 Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti
Endpoints News 2. Juni 2026 #ASCO26: Celcuity plans another FDA filing after positive breast cancer readout
Endpoints News 2. Juni 2026 Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit
Endpoints News 2. Juni 2026 Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis
Endpoints News 2. Juni 2026 Praxis sinks on late-stage study fail for seizure pill, halts second trial